DE60319693D1 - Marker fur lungentumoren - Google Patents

Marker fur lungentumoren

Info

Publication number
DE60319693D1
DE60319693D1 DE60319693T DE60319693T DE60319693D1 DE 60319693 D1 DE60319693 D1 DE 60319693D1 DE 60319693 T DE60319693 T DE 60319693T DE 60319693 T DE60319693 T DE 60319693T DE 60319693 D1 DE60319693 D1 DE 60319693D1
Authority
DE
Germany
Prior art keywords
nucleic acids
tumors
lung cancer
relates
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60319693T
Other languages
English (en)
Other versions
DE60319693T2 (de
Inventor
Johannes Coy
Rainer Hipfel
Birgit Wasser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche MTM Laboratories AG
Original Assignee
Roche MTM Laboratories AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche MTM Laboratories AG filed Critical Roche MTM Laboratories AG
Application granted granted Critical
Publication of DE60319693D1 publication Critical patent/DE60319693D1/de
Publication of DE60319693T2 publication Critical patent/DE60319693T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
DE2003619693 2002-05-21 2003-05-16 Marker fur lungentumoren Expired - Lifetime DE60319693T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20020010275 EP1365032B1 (de) 2002-05-21 2002-05-21 Marker für Lungentumore
EP02010275 2002-05-21
PCT/EP2003/050175 WO2003097871A2 (en) 2002-05-21 2003-05-16 Marker molecules associated with lung tumors

Publications (2)

Publication Number Publication Date
DE60319693D1 true DE60319693D1 (de) 2008-04-24
DE60319693T2 DE60319693T2 (de) 2009-03-05

Family

ID=29286116

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60229920T Expired - Lifetime DE60229920D1 (de) 2002-05-21 2002-05-21 Marker für Lungentumore
DE2003619693 Expired - Lifetime DE60319693T2 (de) 2002-05-21 2003-05-16 Marker fur lungentumoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60229920T Expired - Lifetime DE60229920D1 (de) 2002-05-21 2002-05-21 Marker für Lungentumore

Country Status (9)

Country Link
US (2) US7355025B2 (de)
EP (2) EP1365032B1 (de)
JP (2) JP4520848B2 (de)
AT (2) ATE414789T1 (de)
AU (1) AU2003238077A1 (de)
CA (1) CA2486583C (de)
DE (2) DE60229920D1 (de)
ES (2) ES2316501T3 (de)
WO (1) WO2003097871A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3494231A4 (de) * 2016-08-02 2020-04-15 Georgetown University Verfahren zur identifizierung neuartiger proteine und antigene in krebszellen
WO2021030271A2 (en) 2019-08-09 2021-02-18 Nutcracker Therapeutics, Inc. Methods and apparatuses for manufacturing for removing material from a therapeutic composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US6316208B1 (en) * 1994-01-07 2001-11-13 Memorial Sloan-Kettering Cancer Center Methods for determining isolated p27 protein levels and uses thereof
US6033847A (en) * 1995-02-06 2000-03-07 St. Jude Children's Research Hospital InK4c-p18 and InK4d-p19, inhibitors of cyclin-dependent kinases CDK4 and CDK6, and uses thereof
US5858683A (en) * 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
EP1190044A2 (de) * 1999-06-16 2002-03-27 The John Hopkins University Charakterisierung des transkriptosoms aus hefe
US6806254B2 (en) * 2000-02-03 2004-10-19 Nuvelo, Inc. Methods and materials relating to alpha-2-macroglobulin-like polypeptides and polynucleotides
WO2001061055A2 (en) * 2000-02-17 2001-08-23 Diadexus, Inc. Methods for diagnosing, monitoring, staging, imaging and treating lung cancer via lung cancer specific genes
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20040241651A1 (en) * 2000-04-07 2004-12-02 Alexander Olek Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations
WO2002006294A2 (en) * 2000-07-13 2002-01-24 Genaissance Pharmaceuticals, Inc. Haplotypes of the mmp13 gene

Also Published As

Publication number Publication date
AU2003238077A8 (en) 2003-12-02
WO2003097871A2 (en) 2003-11-27
US20090098544A1 (en) 2009-04-16
US7883896B2 (en) 2011-02-08
US20050176930A1 (en) 2005-08-11
JP2005525826A (ja) 2005-09-02
AU2003238077A1 (en) 2003-12-02
DE60229920D1 (de) 2009-01-02
EP1365032B1 (de) 2008-11-19
EP1506317B1 (de) 2008-03-12
US7355025B2 (en) 2008-04-08
EP1506317A2 (de) 2005-02-16
CA2486583A1 (en) 2003-11-27
WO2003097871A3 (en) 2004-02-05
ATE414789T1 (de) 2008-12-15
DE60319693T2 (de) 2009-03-05
EP1365032A1 (de) 2003-11-26
ES2303595T3 (es) 2008-08-16
ATE389033T1 (de) 2008-03-15
JP2010017194A (ja) 2010-01-28
JP4520848B2 (ja) 2010-08-11
WO2003097871A8 (en) 2004-03-04
CA2486583C (en) 2013-09-24
ES2316501T3 (es) 2009-04-16

Similar Documents

Publication Publication Date Title
WO2004092338A3 (en) Compositions, splice variants and methods relating to cancer specific genes and proteins
WO2004053079A3 (en) Compositions, splice variants and methods relating to ovarian specific genes and proteins
ATE519862T1 (de) Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von gebärmutterhalskrebs
DK1109021T3 (da) Snail, en ny tumoral progressionsmarkör og et targetprotein for nye antitumorale forbindelser
WO2010093872A3 (en) Molecular-based method of cancer diagnosis and prognosis
ATE534902T1 (de) Replikationsproteinn ciz1
EA201290107A1 (ru) Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапии
DE60319693D1 (de) Marker fur lungentumoren
DE69834949D1 (de) Bestimmung der prädisposition für obstruktive lungenerkrankung basierend auf genpolymorphismen der humanen luftweg-trypsin-protease
WO2011073905A8 (en) Novel tumor markers
WO2002040673A3 (en) Compositions and methods relating to lung specific genes and proteins
WO2004053075A3 (en) Compositions, splice variants and methods relating to breast specific genes and proteins
WO2011073901A8 (en) Novel tumor markers
ES2189560B1 (es) Dna polimerasa k, nuevo marcador tumoral.
WO2004050860A3 (en) Compositions, splice variants and methods relating to colon specific genes and proteins
EA200701894A1 (ru) Уровень транскрипции гена timp3 в качестве диагностического маркера немелкоклеточного рака легких
WO2005017183A3 (en) Methylated gene biomarkers for detecting cancer
WO2005017102A3 (en) Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
DE602005021159D1 (de) Bakteriophagen- und prophagen-proteine in der krebsgentherapie
WO2007001399A3 (en) Compositions, splice variants and methods relating to cancer specific genes and proteins
WO2004013311A3 (en) Compositions and methods relating to ovarian specific genes and proteins
WO2003106648A3 (en) COMPOSITIONS AND METHODS RELATED TO BREAST SPECIFIC GENES AND PROTEINS
WO2002064788A3 (en) Compositions and methods relating to lung specific genes and proteins
WO2004052290A3 (en) Compositions, splice variants and methods relating to breast specific genes and proteins
WO2003020899A3 (en) Compositions and methods relating to lung specific genes and proteins

Legal Events

Date Code Title Description
8364 No opposition during term of opposition